Work

CALM study: A phase II study of an intratumorally delivered oncolytic immunotherapeutic agent, coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.3031

Authors: Robert Hans Ingemar Andtbacka, Brendan D. Curti, Howard Kaufman, Gregory A. Daniels, John J. Nemunaitis, Lynn E. Spitler, Sigrun Hallmeyer, Jose Lutzky, Stephen Schultz, Eric D. Whitman, Karl Zhou, Jeffrey Ira Weisberg, Darren Shafren

Institutions: Huntsman Cancer Institute, Rush University Medical Center, Moores Cancer Center, Mary Crowley Cancer Research Center, Northern California Melanoma Center, Oncology Specialists, Mount Sinai Medical Center, Atlantic Health System, Viralytics Limited (Australia)

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2599866288

Cites:

Cited by: 28

Related to: 10